Pfizer Inc. (NYSE: PFE) is under renewed scrutiny as a wave of lawsuits over its contraceptive injection Depo-Provera emerges just days before the company’s third-quarter 2025 earnings announcement on November 4.
The dual spotlight — legal pressure and financial expectations — is shaping up to be one of Pfizer’s most consequential moments in recent years.
The Allegations: Depo-Provera and Brain Tumor Risks
More than 1,300 women in the United States have filed lawsuits against Pfizer, alleging that long-term use of Depo-Provera caused them to develop intracranial meningiomas, a type of benign brain tumor.
The plaintiffs claim the company failed to adequately warn patients and healthcare professionals about potential risks associated with prolonged use of the injectable contraceptive.
Some suits further allege that Pfizer was aware of hormonal dosage risks but continued to market the product aggressively without sufficient cautionary labeling.
A report by The Guardian noted that many of the cases cite medical studies suggesting elevated risk of tumor growth linked to hormonal contraceptive use.
However, Pfizer has strongly disputed these claims, maintaining that Depo-Provera is safe when used as directed and approved by regulators.
Pfizer’s Official Response: A Firm Defense
In response to growing litigation, Pfizer has made clear its intention to “vigorously defend” itself against the accusations.
According to a Reuters report, the company argues that the U.S. Food and Drug Administration (FDA) previously reviewed and declined to approve label changes that would have included tumor risk warnings.
Pfizer’s legal team contends that the lawsuits are preempted by federal law, since FDA oversight governs all prescription drug labeling in the United States.
“Pfizer stands by the safety and efficacy of Depo-Provera when used as directed and will vigorously defend against these claims,” a company spokesperson said in a recent statement.
This stance suggests Pfizer plans to contest the allegations rather than pursue early settlements — a strategy that could extend the legal process but preserve its position on scientific and regulatory grounds.
Investor Focus: Legal Risk Meets Earnings Pressure
For investors, timing could not be more sensitive. Pfizer’s Q3 2025 earnings call, set for November 4 at 10:00 a.m. Eastern Time, will reveal how the company is managing both operational and legal headwinds.
After a post-pandemic slump in COVID-19 vaccine and antiviral sales, Pfizer has been navigating a tough recovery phase. Analysts expect updates on:
-
Legal provisions or reserves set aside for Depo-Provera litigation.
-
Pipeline progress in oncology, mRNA, and rare-disease therapeutics.
-
Revised revenue and cost forecasts for 2026.
Any mention of pending lawsuits during the webcast could influence investor sentiment immediately — either calming markets if addressed confidently, or triggering sell-offs if uncertainty deepens.
Pfizer’s share price has been under pressure for much of 2025, reflecting slower vaccine revenue and investor caution toward the broader pharmaceutical sector.
Legal uncertainty adds to that equation. Investors are wary that large-scale litigation, even if ultimately unsuccessful, can be expensive and distracting.
Yet, some analysts see opportunity: Pfizer’s dividend yield remains attractive, and its R&D portfolio continues to expand, potentially offsetting short-term turbulence.
Historically, Pfizer has weathered similar challenges — including past product liability suits — through strong cash flow, selective settlements, and regulatory compliance defense. Whether that playbook still holds remains to be seen.
Should You Buy Pfizer Stock Before November 4?
With the earnings call approaching, the question on investors’ minds is clear: is Pfizer a buy now, or is it better to wait?
-
Bullish view: The company’s firm defense, diversified pipeline, and strong balance sheet could mean the current dip offers long-term value.
-
Cautious view: Until the scope of the lawsuits and Pfizer’s financial exposure become clearer, waiting until after the earnings call could reduce downside risk.
Either way, the November 4 report will be a defining moment for gauging both legal clarity and business recovery.
The Bigger Picture
Pfizer’s battle over Depo-Provera underscores the growing scrutiny facing major pharmaceutical companies.
As public awareness and litigation risks rise, even legacy drugs are being reexamined in new legal contexts.
For Pfizer, the coming weeks will test its ability to manage reputation, reassure investors, and maintain focus on innovation.
The company’s response on November 4 will not only shape its stock trajectory but could also influence broader discussions about corporate transparency and medical accountability.
Also Read
Etsy Stock Sinks Despite Earnings Beat as CEO Transition Sparks Uncertainty
Can Nvidia Really Hit a $5 Trillion Valuation? Analysts Weigh In